Identification of an Immune Gene-Based Cisplatin Response Model and CD27 as a Therapeutic Target against Cisplatin Resistance for Ovarian Cancer.

Interestingly, Treg scores showed a decreasing trend across the three groups with C3 presenting the highest, followed by C2, and the lowest on C1 ( Figure 2(e) , p value < 0.001).

also in 47,180 other papers